JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB210189

PE Anti-PD-L1抗体[10F.9G2]

PE Anti-PD-L1 antibody [10F.9G2]

Be the first to review this product! Submit a review

|

(2 Publications)

Anti-PD-L1 antibody [10F.9G2] conjugated to PE - suitable for flow cytometry, and reacts with mouse samples. Clone [10F.9G2] is a rat monoclonal antibody and one of the most commonly used clones for flow cytometry.

Design your panel with our interactive flow cytometry panel builder. Click here.

查看别名

CD274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, Cd274, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1

1 Images
Flow Cytometry - PE Anti-PD-L1 antibody [10F.9G2] (AB210189)
  • Flow Cyt

Supplier Data

Flow Cytometry - PE Anti-PD-L1 antibody [10F.9G2] (AB210189)

Flow cytometric analysis of mouse C57BI/6 splenocytes labeling PD-L1 with 0.25 μg ab210189 (solid line) or 0.25 μg PE rat IgG2b isotype control (dashed line).

不同偶联物与剂型 (1)

  • 660 APC

    APC Anti-PD-L1 antibody [10F.9G2]

关键信息

宿主种属

Rat

克隆

Monoclonal

克隆号

10F.9G2

亚型

IgG2b

轻链类型

kappa

偶联物

PE

激发波长/发射波长

Ex: 480;565nm, Em: 578nm

不含载体蛋白

No

反应种属

Mouse

应用

Flow Cyt

applications

免疫原

CHO-mPD-L1 transfectants. Database link Q9EP73

style
left-column

替代产品

Primary Antibodies

AB205921

Anti-PD-L1 antibody [28-8]

BOND RX™ Validated|20ul selling size|Recombinant|KO Validated|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] (AB205921)

  • 4
  • 15
Primary Antibodies

AB209960

Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

  • 0
  • 0
Primary Antibodies

AB213480

Anti-PD-L1 antibody [EPR20529]

RabMAb|Recombinant|KO Validated|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [EPR20529] (AB213480)

  • 5
  • 5
Primary Antibodies

AB213524

Anti-PD-L1 antibody [EPR19759]

BOND RX™ Validated|RabMAb|Recombinant|KO Validated|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [EPR19759] (AB213524)

  • 5
  • 1
Primary Antibodies

AB228415

Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|KO Validated|RabMAb|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD-L1 antibody [73-10] (AB228415)

  • 5
  • 1
Primary Antibodies

AB228462

Anti-PD-L1 antibody [SP142] - C-terminal

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [SP142] - C-terminal (AB228462)

  • 5
  • 2
Primary Antibodies

AB274896

Alexa Fluor® 555 Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|RabMAb|Recombinant|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 555 Anti-PD-L1 antibody [73-10] (AB274896)

  • 4
  • 1

搭配使用产品

Assay Kits

AB277712

Human PD-L1 ELISA Kit [28-8]

Recombinant|SimpleStep

ELISA - Human PD-L1 ELISA Kit [28-8] (AB277712)

  • 0
  • 0
Primary Antibodies

AB237365

Alexa Fluor® 647 Anti-CD8 alpha antibody [EPR21769]

BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 647 Anti-CD8 alpha antibody [EPR21769] (AB237365)

  • 0
  • 0
Primary Antibodies

AB24982

Cy5 ® Anti-CD45.1 antibody [A20]

  • 0
  • 0
Primary Antibodies

AB252149

Alexa Fluor® 488 Anti-CD4 antibody [EPR20122]

RabMAb|Recombinant

Flow Cytometry - Alexa Fluor® 488 Anti-CD4 antibody [EPR20122] (AB252149)

  • 0
  • 0
Primary Antibodies

AB307134

Alexa Fluor® 488 Anti-CD3 antibody [SP162]

BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 488 Anti-CD3 antibody [SP162] (AB307134)

  • 0
  • 0
style
left-column

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p>Use 0.25 μg.</p>" } } }
style
left-column
style
left-column

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein A
纯化说明
ab210189 was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation.
存储溶液
pH: 7.2 Preservative: 0.09% Sodium azide Constituents: 0.87% Sodium chloride, 0.12% Sodium dihydrogen phosphate, 0.1% Gelatin
运输条件
Blue Ice
推荐的短期储存条件
+4°C
推荐的长期储存条件
+4°C
储存信息
Store in the dark
style
left-column

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
style
left-column
style
left-column

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

靶点信息

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188).
See full target information Cd274
style
left-column

文献 (2)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 9:4777 PubMed30429468

2018

MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma.

Applications

Unspecified application

Species

Unspecified reactive species

Meiying Wu,Haixian Zhang,Changjun Tie,Chunhong Yan,Zhiting Deng,Qian Wan,Xin Liu,Fei Yan,Hairong Zheng

Microcirculation (New York, N.Y. : 1994) 9:133-45 PubMed11932780

2002

Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.

Applications

Unspecified application

Species

Unspecified reactive species

Michael J Eppihimer,Jason Gunn,Gordon J Freeman,Edward A Greenfield,Tetyana Chernova,Jamie Erickson,John P Leonard
View all publications
style
left-column
style
left-column
style
right-column

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂，为您科研的每一步提供支持。若我们的产品未能达到预期性能，我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com